AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Breakpoints for Enterobacteralis and Pseudomonas
This week we'll be deep diving into the immune glycosides. So gentamycin, Tobar mycin, and ammakason among them. We might even talk a little bit about our dear friend, playsomycin. To start this discussion, I want to go from each organization talking about enterobacteralis and pseudomonas. What breakpoints have we been operating on, and where did the state come from?